MA40605A - Composé pyrazolothiazole et médicament - Google Patents
Composé pyrazolothiazole et médicamentInfo
- Publication number
- MA40605A MA40605A MA040605A MA40605A MA40605A MA 40605 A MA40605 A MA 40605A MA 040605 A MA040605 A MA 040605A MA 40605 A MA40605 A MA 40605A MA 40605 A MA40605 A MA 40605A
- Authority
- MA
- Morocco
- Prior art keywords
- present
- jak1
- medication
- compounds
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
L'objectif de la présente invention est de fournir un composé ayant un effet inhibiteur exceptionnel de jak1. Des exemples de la présente invention comprennent des composés pyrazolothiazole représentés par la formule générale [i], ainsi que des sels pharmaceutiquement acceptables de ceux-ci. Les composés de la présente invention ont une activité inhibitrice de jak1. étant donné cette activité inhibitrice jak1, les composés de la présente invention ont également un effet immunosuppresseur (contre, par exem
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014177969 | 2014-09-02 | ||
PCT/JP2015/074935 WO2016035814A1 (fr) | 2014-09-02 | 2015-09-02 | Composé pyrazolothiazole et médicament |
Publications (2)
Publication Number | Publication Date |
---|---|
MA40605A true MA40605A (fr) | 2017-07-12 |
MA40605B1 MA40605B1 (fr) | 2020-10-28 |
Family
ID=55439874
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA40605A MA40605B1 (fr) | 2014-09-02 | 2015-09-02 | Composé pyrazolothiazole et médicament |
Country Status (33)
Country | Link |
---|---|
US (2) | US9937176B2 (fr) |
EP (1) | EP3190116B1 (fr) |
JP (1) | JP6558372B2 (fr) |
KR (1) | KR102294330B1 (fr) |
CN (1) | CN107108653B (fr) |
AU (1) | AU2015312886B2 (fr) |
BR (1) | BR112017003800B1 (fr) |
CA (1) | CA2959721C (fr) |
CL (1) | CL2017000478A1 (fr) |
CO (1) | CO2017002982A2 (fr) |
CY (1) | CY1123320T1 (fr) |
DK (1) | DK3190116T3 (fr) |
ES (1) | ES2827243T3 (fr) |
HR (1) | HRP20201382T1 (fr) |
HU (1) | HUE050565T2 (fr) |
IL (1) | IL250729B (fr) |
LT (1) | LT3190116T (fr) |
MA (1) | MA40605B1 (fr) |
MX (1) | MX2017002488A (fr) |
MY (1) | MY181814A (fr) |
NZ (1) | NZ729494A (fr) |
PE (1) | PE20170668A1 (fr) |
PH (1) | PH12017500383B1 (fr) |
PL (1) | PL3190116T3 (fr) |
PT (1) | PT3190116T (fr) |
RS (1) | RS60798B1 (fr) |
RU (1) | RU2688660C2 (fr) |
SG (2) | SG11201701447UA (fr) |
SI (1) | SI3190116T1 (fr) |
TW (1) | TWI679205B (fr) |
UA (1) | UA121869C2 (fr) |
WO (1) | WO2016035814A1 (fr) |
ZA (1) | ZA201701492B (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI679205B (zh) * | 2014-09-02 | 2019-12-11 | 日商日本新藥股份有限公司 | 吡唑并噻唑化合物及醫藥 |
TWI712604B (zh) | 2016-03-01 | 2020-12-11 | 日商日本新藥股份有限公司 | 具jak抑制作用之化合物之結晶 |
US11167953B2 (en) | 2017-06-09 | 2021-11-09 | Mitsubishi Electric Corporation | Passenger conveyor |
US20230117592A1 (en) * | 2019-12-23 | 2023-04-20 | Sri International | Lipoxygenase inhibitors |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3600390A1 (de) | 1986-01-09 | 1987-07-16 | Hoechst Ag | Diarylalkyl-substituierte alkylamine, verfahren zu ihrer herstellung, ihre verwendung sowie sie enthaltende arzneimittel |
US5017212A (en) * | 1986-03-20 | 1991-05-21 | Takeda Chemical Industries, Ltd. | Sulfonylurea compounds and herbicidal use |
US5082847A (en) | 1990-07-18 | 1992-01-21 | Syntex (U.S.A.) Inc. | Carbostyril compounds connected via an oxyalkyl group with a piperidine ring and having pharmaceutical utility |
GB0216383D0 (en) | 2002-07-13 | 2002-08-21 | Astrazeneca Ab | Compounds |
EP1704145B1 (fr) | 2004-01-12 | 2012-06-13 | YM BioSciences Australia Pty Ltd | Inhibiteurs selectifs de kinases |
WO2005105779A1 (fr) | 2004-04-28 | 2005-11-10 | Pfizer Limited | Derives 3-heterocyclyl-4-phenyl-triazole comme inhibiteurs de la vasopressine par recepteur |
SG151327A1 (en) * | 2005-09-30 | 2009-04-30 | Vertex Pharmaceuticals Incopor | Deazapurines useful as inhibitors of janus kinases |
PT1951684T (pt) * | 2005-11-01 | 2016-10-13 | Targegen Inc | Inibidores de cinases de tipo biaril-meta-pirimidina |
AR060316A1 (es) | 2006-01-17 | 2008-06-11 | Vertex Pharma | Azaindoles de utilidad como inhibidores de janus quinasas |
ES2602577T3 (es) | 2008-03-11 | 2017-02-21 | Incyte Holdings Corporation | Derivados de azetidina y ciclobutano como inhibidores de JAK |
ES2396126T3 (es) * | 2008-04-15 | 2013-02-19 | Eisai R&D Management Co., Ltd. | Compuesto de 3-fenilpirazol[5,1-b]tiazol |
JO3041B1 (ar) | 2008-07-25 | 2016-09-05 | Galapagos Nv | مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية |
JP5490137B2 (ja) * | 2008-12-19 | 2014-05-14 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | プロテインキナーゼ阻害薬としての二環式ピラゾール |
TWI462920B (zh) | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
CA2782720A1 (fr) | 2009-12-18 | 2011-06-23 | Pfizer Inc. | Composes pyrrolo[2,3-d]pyrimidines |
TW201124078A (en) | 2009-12-22 | 2011-07-16 | Du Pont | Fungicidal 2-(bicyclic aryloxy) carboxamides |
EP2338888A1 (fr) | 2009-12-24 | 2011-06-29 | Almirall, S.A. | Dérivés d'imidazopyridine en tant qu'inhibiteurs JAK |
JP2011136925A (ja) | 2009-12-28 | 2011-07-14 | Dainippon Sumitomo Pharma Co Ltd | 含窒素二環性化合物 |
MX2012008049A (es) | 2010-01-12 | 2012-08-01 | Hoffmann La Roche | Compuestos heterociclicos triciclicos, composiciones y metodos de uso de los mismos,. |
UY33213A (es) | 2010-02-18 | 2011-09-30 | Almirall Sa | Derivados de pirazol como inhibidores de jak |
CA2801032A1 (fr) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Derives de n-sulfonylbenzamide utiles comme inhibiteurs du canal sodique voltage-dependant |
WO2012022045A1 (fr) | 2010-08-20 | 2012-02-23 | Hutchison Medipharma Limited | Composés pyrrolopyrimidiniques et leurs utilisations |
EP2616443A1 (fr) | 2010-09-14 | 2013-07-24 | Exelixis, Inc. | Dérivés de la phtalazine comme inhibiteurs de jak1 |
US8937077B2 (en) | 2010-10-22 | 2015-01-20 | Merck Sharp & Dohme Corp. | Bicyclic diamines as janus kinase inhibitors |
WO2012085176A1 (fr) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Composés pyrazinones tricycliques, leurs compositions et leurs procédés d'utilisation en tant qu'inhibiteurs de janus kinase |
WO2013025628A1 (fr) * | 2011-08-15 | 2013-02-21 | Ligand Pharmaceuticals Incorporated | Composés et procédés d'inhibition de janus kinase |
TWI679205B (zh) * | 2014-09-02 | 2019-12-11 | 日商日本新藥股份有限公司 | 吡唑并噻唑化合物及醫藥 |
-
2015
- 2015-09-01 TW TW104128865A patent/TWI679205B/zh active
- 2015-09-02 NZ NZ729494A patent/NZ729494A/en unknown
- 2015-09-02 PL PL15838466T patent/PL3190116T3/pl unknown
- 2015-09-02 AU AU2015312886A patent/AU2015312886B2/en active Active
- 2015-09-02 CA CA2959721A patent/CA2959721C/fr active Active
- 2015-09-02 SG SG11201701447UA patent/SG11201701447UA/en unknown
- 2015-09-02 MX MX2017002488A patent/MX2017002488A/es unknown
- 2015-09-02 HU HUE15838466A patent/HUE050565T2/hu unknown
- 2015-09-02 CN CN201580058944.7A patent/CN107108653B/zh active Active
- 2015-09-02 DK DK15838466.9T patent/DK3190116T3/da active
- 2015-09-02 KR KR1020177008967A patent/KR102294330B1/ko active IP Right Grant
- 2015-09-02 LT LTEP15838466.9T patent/LT3190116T/lt unknown
- 2015-09-02 JP JP2016546669A patent/JP6558372B2/ja active Active
- 2015-09-02 ES ES15838466T patent/ES2827243T3/es active Active
- 2015-09-02 EP EP15838466.9A patent/EP3190116B1/fr active Active
- 2015-09-02 MY MYPI2017700677A patent/MY181814A/en unknown
- 2015-09-02 BR BR112017003800-5A patent/BR112017003800B1/pt active IP Right Grant
- 2015-09-02 RS RS20201081A patent/RS60798B1/sr unknown
- 2015-09-02 SI SI201531340T patent/SI3190116T1/sl unknown
- 2015-09-02 RU RU2017110535A patent/RU2688660C2/ru active
- 2015-09-02 SG SG10201901676UA patent/SG10201901676UA/en unknown
- 2015-09-02 PE PE2017000370A patent/PE20170668A1/es unknown
- 2015-09-02 US US15/505,767 patent/US9937176B2/en active Active
- 2015-09-02 UA UAA201702990A patent/UA121869C2/uk unknown
- 2015-09-02 WO PCT/JP2015/074935 patent/WO2016035814A1/fr active Application Filing
- 2015-09-02 MA MA40605A patent/MA40605B1/fr unknown
- 2015-09-02 PT PT158384669T patent/PT3190116T/pt unknown
-
2017
- 2017-02-23 IL IL250729A patent/IL250729B/en active IP Right Grant
- 2017-02-28 ZA ZA2017/01492A patent/ZA201701492B/en unknown
- 2017-02-28 CL CL2017000478A patent/CL2017000478A1/es unknown
- 2017-03-01 PH PH12017500383A patent/PH12017500383B1/en unknown
- 2017-03-27 CO CONC2017/0002982A patent/CO2017002982A2/es unknown
- 2017-12-04 US US15/830,181 patent/US9999622B2/en active Active
-
2020
- 2020-08-31 HR HRP20201382TT patent/HRP20201382T1/hr unknown
- 2020-09-04 CY CY20201100832T patent/CY1123320T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA46337A (fr) | Composé de pyridine | |
PH12017502171B1 (en) | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | |
GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
MA33330B1 (fr) | Quinazolines substituées comme fongicides | |
TN2020000125A1 (en) | Amino-fluoropiperidine derivative as kinase inhibitor | |
EA201891703A1 (ru) | Соединения бензопиразола и их аналоги | |
MA38390B1 (fr) | Composés tétrahydropyrrolothiazines | |
MY196572A (en) | Amino-Methyl Piperidine Derivative as Kinase Inhibitor | |
EA201592199A1 (ru) | Производные бипиразола в качестве ингибиторов jak | |
MA38039A1 (fr) | Composés de céphem substitués en position 2 | |
SA520412335B1 (ar) | مشتقات أوكسي فلورو ببريدين كمثبط كيناز | |
BRPI0511433A (pt) | derivados de quinolina substituìda como inibidores de cinesina mitótica | |
MA40605A (fr) | Composé pyrazolothiazole et médicament | |
MA34385B1 (fr) | Composés hétérocycliques condensés comme inhibiteurs de phosphodiestérases (pdes) | |
MA38583B1 (fr) | Dérivés de dolastatine 10 et d'auristatines | |
MA39152A1 (fr) | Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine | |
MA39315A1 (fr) | Dérivés de pyridazine à utiliser dans la prévention ou le traitement d'un trouble ataxique | |
NZ746906A (en) | Oxaborole esters and uses thereof | |
EA201692557A1 (ru) | Хинолизиноновые производные в качестве ингибиторов pi3k | |
SA519401827B1 (ar) | [3، 4- d] مشتق بيريدو بيريميدين وملح مقبول صيدلانياً منه | |
MA30664B1 (fr) | Derive d'aminoalcool et immunodepresseur le contenant en tant que principe actif. | |
MX2019011558A (es) | Nuevos compuestos sustituidos de n'-hidroxicarbamimidoil-1,2,5-oxa diazol como inhibidores de indolamina 2,3-dioxigenasa (ido). | |
MX2019012640A (es) | Metodos de uso de derivados de benzotriazoles trisustituidos como inhibidores de dihidroorotato-oxigenasa. | |
WO2014062852A3 (fr) | Dérivés de thiohydantoïnes et leurs utilisations | |
MA38991A1 (fr) | Dérivés d'indole-urée substitués par un glucopyranosyle et leur utilisation à titre d'inhibiteurs de sglt |